Published in:
Open Access
01-12-2020 | Research
Pilot study of a basic individualized cognitive behavioral therapy program for chronic pain in Japan
Authors:
Hiroki Hosogoshi, Kazunori Iwasa, Takaki Fukumori, Yuriko Takagishi, Yoshitake Takebayashi, Tomonori Adachi, Yuki Oe, Yukino Tairako, Yumiko Takao, Hiroyuki Nishie, Ayako Kanie, Masaki Kitahara, Kiyoka Enomoto, Hirono Ishii, Issei Shinmei, Masaru Horikoshi, Masahiko Shibata
Published in:
BioPsychoSocial Medicine
|
Issue 1/2020
Login to get access
Abstract
Background
Chronic pain is a major health problem, and cognitive behavioral therapy (CBT) is its recommended treatment; however, efforts to develop CBT programs for chronic pain and assess their feasibility are remarkably delayed in Asia. Therefore, we conducted this pilot study to develop a basic individualized CBT for chronic pain (CBT-CP) and assessed its feasibility for use in Japan.
Methods
Our study was an open-labeled before–after trial without a control group conducted cooperatively in five Japanese tertiary care hospitals. Of 24 outpatients, 15, age 20–80, who experienced chronic pain for at least three months were eligible. They underwent an eight-session CBT-CP consisting of relaxation via a breathing method and progressive muscle relaxation, behavioral modification via activity pacing, and cognitive modification via cognitive reconstruction. The EuroQol five-dimensional questionnaire five level (EQ5D-5 L) assessment as the primary outcome and quality of life (QOL), pain severity, disability, catastrophizing, self-efficacy, and depressive symptoms as secondary outcomes were measured using self-administered questionnaires at baseline, post-treatment, and 3-month follow-up. Intention-to-treat analyses were conducted.
Results
Effect size for EQ5D-5 L score was medium from baseline to post-treatment (Hedge’s g = − 0.72, 90% confidence interval = − 1.38 to − 0.05) and up to the 3-month follow-up (g = − 0.60, CI = − 1.22 to 0.02). Effect sizes for mental and role/social QOL, disability, catastrophizing, self-efficacy, and depressive symptoms were medium to large, although those for pain severity and physical QOL were small. The dropout rate was acceptably low at 14%. No severe adverse events occurred.
Conclusion
The findings suggest that CBT-CP warrants a randomized controlled trial in Japan.
Trial registration
University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR),
UMIN000020880. Registered on 04 February 2016.